Want to see HK:1951 full AI Analyst Report?
Top Page
Jinxin Fertility Group Ltd.
(1951)
Select Model
Select Model
Rating:55Neutral
Price Target:
HK$2.50
▲(10.13% Upside)
Action:Reiterated
Date:07/17/26
The score is weighed down primarily by the 2025 earnings reversal (revenue decline and a large net loss) and weaker free cash flow, partially offset by a manageable balance sheet and still-positive operating cash flow. Technicals are moderately supportive in the near term (above key short-to-medium moving averages with positive momentum), while valuation remains challenged due to the negative P/E despite a modest dividend yield.
Positive Factors
Manageable Leverage
Moderate leverage and substantial equity provide financial flexibility for a healthcare services operator. This balance-sheet position can help Jinxin absorb earnings volatility and fund ongoing operations without relying excessively on additional borrowing.
Negative Factors
Revenue Contraction
The reversal from prior expansion to declining revenue signals weaker demand, utilization, pricing, or contribution from operating facilities. Sustained contraction would reduce scale benefits and make it harder to restore profitability across the fertility services network.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
Moderate leverage and substantial equity provide financial flexibility for a healthcare services operator. This balance-sheet position can help Jinxin absorb earnings volatility and fund ongoing operations without relying excessively on additional borrowing.
Read all positive factors
Jinxin Fertility Group Ltd. (1951) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$5.64B
Dividend Yield1.98%
Average Volume (3M)13.87M
Price to Earnings (P/E)25.1
Beta (1Y)1.26
Revenue Growth6.52%
EPS GrowthN/A
CountryHK
Employees3,128
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.07
Shares Outstanding2,705,044,000
10 Day Avg. Volume10,986,250
30 Day Avg. Volume13,872,161
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.64
Price to Sales (P/S)2.27
P/FCF Ratio26.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.29Price Target Upside44.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$2.86B
Jinxin Fertility Group Ltd. Business Overview & Revenue Model
Company Description
Jinxin Fertility Group Limited is an investment holding company that specializes in providing assisted reproductive services (ARS) across both China and the United States. Its core offerings primarily include two types of treatment: artificial ins...
How the Company Makes Money
null...
Jinxin Fertility Group Ltd. Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
63
Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.69B | 2.58B | 2.81B | 2.79B | 2.36B | 1.84B |
| Gross Profit | 947.47M | 818.44M | 1.10B | 1.18B | 913.13M | 771.48M |
| EBITDA | 653.44M | 538.60M | 645.06M | 682.02M | 476.21M | 494.08M |
| Net Income | 168.59M | -950.88M | 283.10M | 344.72M | 121.12M | 339.90M |
Balance Sheet | ||||||
| Total Assets | 13.82B | 13.97B | 14.98B | 14.90B | 15.23B | 12.83B |
| Cash, Cash Equivalents and Short-Term Investments | 804.61M | 906.17M | 570.82M | 852.90M | 1.40B | 1.93B |
| Total Debt | 3.00B | 2.96B | 2.71B | 2.55B | 4.16B | 2.09B |
| Total Liabilities | 4.86B | 4.77B | 4.63B | 4.71B | 6.50B | 4.07B |
| Stockholders Equity | 8.91B | 9.15B | 10.27B | 10.09B | 8.64B | 8.55B |
Cash Flow | ||||||
| Free Cash Flow | 124.58M | 218.33M | 489.30M | 510.92M | -417.65M | 263.62M |
| Operating Cash Flow | 260.66M | 475.94M | 629.20M | 684.48M | 541.74M | 343.45M |
| Investing Cash Flow | -16.27M | -154.86M | -293.27M | -375.04M | -1.38B | -1.57B |
| Financing Cash Flow | -32.81M | -6.66M | -458.29M | -950.45M | 460.14M | 955.05M |
Jinxin Fertility Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | HK$6.04B | 29.49 | 2.50% | 0.39% | 1.59% | -58.55% | |
55 Neutral | HK$5.64B | 25.12 | 1.87% | 1.98% | 6.52% | ― | |
52 Neutral | HK$958.02M | -19.45 | -1.56% | 10.22% | 7.95% | 60.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | HK$1.18B | 83.33 | 0.48% | 1.03% | -3.26% | ― | |
38 Underperform | HK$572.07M | -3.25 | -8.65% | ― | 47.93% | 65.94% |
* Healthcare Sector Average
HK:1951
Jinxin Fertility Group Ltd.
2.12
-0.63
-23.09%
HK:0286
Aidigong Maternal & Child Health
1.31
0.00
0.00%
HK:9960
Kindstar Globalgene Technology, Inc.
0.93
-0.42
-31.37%
HK:3886
Town Health International Medical Group Ltd.
0.17
-0.09
-33.59%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
10.00
-4.11
-29.13%
HK:2453
Concord Healthcare Group Co., Ltd. Class H
0.75
-2.41
-76.27%
Jinxin Fertility Group Ltd. Corporate Events
Jinxin Fertility Sets August Board Meeting to Approve Interim Results
Aug 7, 2026
Jinxin Fertility Group Limited has scheduled a board meeting for August 21, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026 and to authorize their publication. The announcement signals that the c...
Jinxin Fertility Posts Solid Growth in Fertility and Obstetrics Services for H1 2026
Jul 21, 2026
Jinxin Fertility Group reported that new patient visits for infertility rose 9.1% to 24,169 and oocyte pick up cycles increased 6.1% to 14,653 in the first half of 2026, underscoring steady growth in demand for its core reproductive services. The ...
Jinxin Fertility Signals Sharp Profit Turnaround on Recovery in Core Markets
Jul 21, 2026
Jinxin Fertility Group Limited has issued a positive profit alert, forecasting a swing from a net loss of about RMB1.04 billion in the first half of 2025 to a net profit of at least RMB90 million in the first half of 2026. The group also expects E...
Jinxin Fertility Shareholders Approve All AGM Resolutions and Final Dividend
Jun 25, 2026
Jinxin Fertility Group Limited reported that all resolutions at its 25 June 2026 annual general meeting were passed by poll, including the adoption of the 2025 audited financial statements and the re-election of four retiring directors. Shareholde...
Jinxin Fertility Plans Shanghai Asset-Backed Securities to Cut Leverage
Jun 22, 2026
Jinxin Fertility Group Limited plans to launch an asset-backed securities programme on the Shanghai Stock Exchange, backed mainly by a building in Shenzhen owned by its subsidiary Shenzhen Hengyu Lianxiang Investment Development Co., Ltd., which h...
Jinxin Fertility Sets 2026 AGM to Approve Dividend, Board Mandates
Jun 2, 2026
Jinxin Fertility Group has called its annual general meeting for June 25, 2026, in Chengdu, where shareholders will vote on the adoption of the 2025 audited financial statements, the re-election of four retiring directors, and authorization for th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.